PledPharma AB (publ) Stock Nasdaq Stockholm
Stocks
SE0003815604
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 3.67B 379M 326M 309M 280M 525M 36.17B 528M 1.41B 18.4B 1.42B 1.39B 58.15B | P/E 2026 * |
-9.07x | P/E 2027 * | -17.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3.12B 322M 277M 262M 238M 446M 30.73B 448M 1.2B 15.63B 1.21B 1.18B 49.4B | EV / Sales 2026 * |
5.66x | EV / Sales 2027 * | 10.1x |
| Free-Float |
37.69% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : PledPharma AB (publ)
| 1 day | -1.07% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 2017-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 47 | 2017-12-30 |
Tiago Nune
CTO | Chief Tech/Sci/R&D Officer | - | 2026-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 2016-12-31 | |
| Director/Board Member | 65 | 2016-12-31 | |
Mats Blom
CHM | Chairman | 61 | 2024-05-05 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.07% | -0.74% | - | - | 379M | |
| -2.11% | -1.68% | +44.52% | +95.15% | 66.93B | |
| -0.23% | -4.45% | +32.50% | +75.75% | 61.97B | |
| +1.67% | +2.47% | -11.32% | +380.54% | 28.27B | |
| -1.05% | -4.43% | +28.84% | +10.59% | 24.59B | |
| +0.34% | -6.78% | -0.01% | -16.35% | 24.3B | |
| +0.43% | -3.37% | +16.22% | -17.99% | 19.41B | |
| -3.03% | -2.29% | +181.72% | +335.27% | 16.77B | |
| -1.94% | -4.94% | -8.15% | +483.69% | 14.18B | |
| -2.28% | -4.90% | +43.35% | +154.05% | 13.91B | |
| Average | -0.93% | -3.46% | +36.41% | +166.74% | 30.04B | |
| Weighted average by Cap. | -0.84% | -3.06% | +34.15% | +133.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 551M 56.87M 49M 46.4M 42.05M 78.9M 5.43B 79.3M 212M 2.76B 214M 209M 8.73B | 328M 33.83M 29.15M 27.6M 25.02M 46.93M 3.23B 47.17M 126M 1.64B 127M 124M 5.2B |
| Net income | 161M 16.64M 14.34M 13.58M 12.31M 23.09M 1.59B 23.21M 62.01M 809M 62.51M 61.14M 2.56B | -134M -13.85M -11.94M -11.3M -10.24M -19.22M -1.32B -19.32M -51.62M -673M -52.03M -50.89M -2.13B |
| Net Debt | -552M -56.94M -49.06M -46.45M -42.11M -78.99M -5.44B -79.39M -212M -2.77B -214M -209M -8.75B | -353M -36.44M -31.39M -29.73M -26.94M -50.55M -3.48B -50.8M -136M -1.77B -137M -134M -5.6B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
